1. Canioni D, Jabado N, MacIntyre E, Patey N, Emile JF, Brousse N. Lymphoproliferative disorders in children with primary immunodeficiency; immunological status may be more predictive of the outcome than other criteria. Histopathol2001;38:146-159.
2. Rizzo K, NassiriM.Diagnostic Workup of Small B Cell Lymphomas: A Laboratory Perspective Lymphoma
Volume 2012:Article ID 346084,doi:10.1155/2012/346084
3. Dorfman RF, Gelb AB, Hendrickson MR. Composite lymphoma Am J Pathol 1992; 40: 959-76
4. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. –Its significance in cancer and cancer therapy. Cancer 1994; 73:2013-26.
5. Anderson MA, Huang D,RobertsA. Targeting BCL2 for the Treatment of Lymphoid Malignancies. SeminHematol 2014; 51:219–227.
6. Gaulard P, Agay MF, M. Peuchmaur, N Brousse, C. Gisselbrecht, P. Solal-Celignyet al. Bcl-2 expression in diffuse aggressive lymphoma. Am J Pathol 1992; 140:1089-95.
7. Wheaton S, Netser J, Guinee D, Rahn M, Perkins S.BCL-2 and Bax protein expression and indolent versus aggressive B-cell non- Hodgkin’s lymphomas. Human Pathology 1998;29: 820-25.
8. Korsemeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. BCL-2 / Bax: a rheostat that regulates an antioxidant pathway and cell death. Semin Cancer Biol. 1993; 4: 327-32.
9. Sahu SK, Choudhuri T. Lack of Association between Bax Promoter (-248G>A) Single Nucleotide Polymorphism and Susceptibility towards Cancer: Evidence from a Meta-Analysis. PLoS ONE 2013; 8(10): e77534. doi:10.1371/journal.pone.0077534
10. Soiniy Y, Paakko P. Apoptosis and ex-pression of caspases 3, 6 and 8 in malignant non- Hodkins lymphomas. APMIS. 1999;107: 1043- 50.
11. Oltavi ZN, Millman CL & Korsmeyer SJ.Bcl-2 heterodimers in vivo with a conserved homologue, Bax, that accelerates programmed cell death. 1993.Cell;74 :609–619.
12. M R. Hussein, TM Al-SabaeMarcelle, N. Georgis. Analysis of the Bcl-2 and p53 Protein Expression
in the LymphoproliferativeLesions in the Upper Egypt. Cancer Biology & Therapy 2005;4: 324-28.
13. Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC . Prognostic significance of Bax protein expression in diffuse agressive non-Hodkin’ s lymphoma. Blood. 1997; 90: 3173-8
14. Winter JNN, Andersen J, Reed JC,KrajewskiS,Variakojis D, Bauer KDet.al. Bcl-2 expression correlates with lower proliferative activity in the intermediate-and high grade non- Hodkins lymphomas: an Eastern Cooperative Oncology group and southwest Oncology group cooperative laboratory study. Blood. 1998; 91: 1391-8.
15. Flora Tzifi, Christina Economopoulou, DimitriosGourgiotis, AlexandrosArdavanis,SotiriosPapageorgiou,AndreasScorilas. The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Advances in Hematology
Volume 2012, Article ID 524308, 15 pages
16. El-Esawy, B. H. The Immunohistochemistry Based Evaluation of Bcl-2 in B Non Hodgkin lymphoma & Its Prognostic Significance. Life Sci J 2013;10: 3290-3295
17. NY Samuel, Matthew S. Davids. Selective Bcl-2 Inhibition to Treat Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. Clinical Advances in Hematology & Oncology 2014;12: 224-29.
18. CD Goia, AR Lupu, C Bleotu, C Antipa, Lvelt, E Popa, G Constantinescu, Correlation Between Pro- And Anti-Apoptotic Gene Expression And Telomerase Activity In B- Cell Lymphomas. Proc. Rom. Acad2008;3:169–174
19. Charalambous GK, Gomatos IP, Konstadoulakis MM, MessarisEG, Manouras AJ,
Apostolou AE et.al. Protein expression of bax, bcl-2, and p53 in patients with nonHodgkin’s gastric lymphoma: Prognostic significance. World J Surg 2000; 24:608-14.
20. Burra U, Shanthi P, Krishnan KB, Madhavan M. P 53 and PCNA in Non Hodgkin’s lymphoma—an immunohistochemical evaluation. Indian J PatholMicrobiol 2000; 43:61-4.
21. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54:3131-5.
22. Korkolopoulou P, Oates J, Kittas C, Crocker J. P-53, c-myc, P-62 and proliferating cell nuclear antigen (PCNA) expression in no Hodgkin’s lymphomas. J Clin Pathol.1994; 47: 9-14.
23.
Rabenhorst SH,
Burini RC,
Schmitt FC. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material. Pathology. 1996; 28:12-6.
24. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Ioannis A.et al: Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immuno- globulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-50.
25. Garcia JF, Camacho FI, MorenteM,Fraga M, Montalban C, Alvaro T.et.al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: Analyses using tissue microarrays. Blood 2003;101:681-689
26. SJ. Sup, C A. Aleman ̃y, B Pohlman, P Elson, S Malhi, SThakkar. Expression of bcl-2 in Classical Hodgkin’s Lymphoma: An Independent Predictor of Poor Outcome. J ClinOncol 2005;23:3773-79.
27. EDerenzin,AYounes. Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. Genome Medicine 2011, 3:26
28. Brousset P, Benharroch D, Krajewski S, Laurent G, Meggetto F, Rigal-Huguet F.et.al. Frequent expression of cell death inducing gene Bax in Reed Sternberg cells of Hodgkin’s disease. Blood 1996; 87: 2470-5.
29. KanavarosP, Stefanaki K, Viachonikolis J. Expression of P-53, P-21 / Waf1, BCL-2, Bax, Rb and Ki67 proteins in Hodgkin’s lymphomas. Histopathol 2000;15: 445-53.
30. Smolewski P, Niewiadomska H, Blonski JZ, Robak T, Krykowski E.et.al. Expression of proliferating cell nuclear antigen (PCNA) and P-53, BCL-2 or C-erb B -2 proteins on Reed Sternberg cells: prognostic significance in Hodgkin’s disease. Neoplasma.1998; 45: 140-7.
)